Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Margalida CalafatPaola TorresJoan Tosca-CuquerellaRubén Sánchez-AldehueloMontserrat RiveroMarisa IborraMaría González-VivoIsabel VeraLuisa de CastroLuis BujandaManuel Barreiro-de AcostaCarlos González-MuñozaXavier Calvet CalvoJosé Manuel BenítezMónica Llorente-BarrioGerard SurísFiorella CañeteLara Arias-GarcíaDavid MonfortAndrés Castaño-GarcíaFrancisco Javier Garcia-AlonsoJosé M HuguetIgnacio Marín-JímenezRufo LorenteAlbert Martín-CardonaJuan Ángel FerrerPatricia CamoFrancisco Javier García-AlonsoRamón PajaresFernando GomollónJesús Castro-PoceiroJair Morales-AlvaradoJordina LlaóAndrés RodríguezCristina RodríguezPablo Pérez-GalindoMercè NavarroNuria Jiménez-GarcíaMarta Carrillo-PalauIsabel Blázquez-GómezEva SeséPedro AlmelaPatricia Ramírez de la PiscinaCarlos TaxoneraIago Rodríguez-LagoLidia CabrinetyMilagros VelaMiguel MínguezFrancisco Mesonero GismeroMaría José GarcíaMariam AguasLucía MárquezMarisol Silva PortoJuan R PinedaKoldo GarciaFederico BertolettiEduard BrunetMíriam MañosaEugeni DomènechPublished in: Therapeutic advances in gastroenterology (2024)
The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.
Keyphrases